These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 28027514)
1. EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. Liu CY; Huang TT; Huang CT; Hu MH; Wang DS; Wang WL; Tsai WC; Lee CH; Lau KY; Yang HP; Chen MH; Shiau CW; Tseng LM; Chen KF Eur J Cancer; 2017 Feb; 72():112-123. PubMed ID: 28027514 [TBL] [Abstract][Full Text] [Related]
2. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression. Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219 [TBL] [Abstract][Full Text] [Related]
3. Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Yu HC; Hung MH; Chen YL; Chu PY; Wang CY; Chao TT; Liu CY; Shiau CW; Chen KF Cell Death Dis; 2014 Jul; 5(7):e1359. PubMed ID: 25077545 [TBL] [Abstract][Full Text] [Related]
4. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320 [TBL] [Abstract][Full Text] [Related]
5. CIP2A is a target of bortezomib in human triple negative breast cancer cells. Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901 [TBL] [Abstract][Full Text] [Related]
6. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871 [TBL] [Abstract][Full Text] [Related]
7. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503 [TBL] [Abstract][Full Text] [Related]
8. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280 [TBL] [Abstract][Full Text] [Related]
9. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431 [TBL] [Abstract][Full Text] [Related]
10. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A. Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452 [TBL] [Abstract][Full Text] [Related]
12. Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. Pallai R; Bhaskar A; Sodi V; Rice LM Transcription; 2012; 3(6):323-35. PubMed ID: 23117818 [TBL] [Abstract][Full Text] [Related]
13. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913 [TBL] [Abstract][Full Text] [Related]
14. Micropeptide CIP2A-BP encoded by LINC00665 inhibits triple-negative breast cancer progression. Guo B; Wu S; Zhu X; Zhang L; Deng J; Li F; Wang Y; Zhang S; Wu R; Lu J; Zhou Y EMBO J; 2020 Jan; 39(1):e102190. PubMed ID: 31755573 [TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer. Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826 [TBL] [Abstract][Full Text] [Related]
16. Sideroflexin-1 promotes progression and sensitivity to lapatinib in triple-negative breast cancer by inhibiting TOLLIP-mediated autophagic degradation of CIP2A. Andriani L; Ling YX; Yang SY; Zhao Q; Ma XY; Huang MY; Zhang YL; Zhang FL; Li DQ; Shao ZM Cancer Lett; 2024 Aug; 597():217008. PubMed ID: 38849012 [TBL] [Abstract][Full Text] [Related]
17. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919 [TBL] [Abstract][Full Text] [Related]
18. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1. Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903 [TBL] [Abstract][Full Text] [Related]
19. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis. Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585 [TBL] [Abstract][Full Text] [Related]
20. Carfilzomib induces leukaemia cell apoptosis via inhibiting ELK1/KIAA1524 (Elk-1/CIP2A) and activating PP2A not related to proteasome inhibition. Liu CY; Hsieh FS; Chu PY; Tsai WC; Huang CT; Yu YB; Huang TT; Ko PS; Hung MH; Wang WL; Shiau CW; Chen KF Br J Haematol; 2017 Jun; 177(5):726-740. PubMed ID: 28340282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]